SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addit...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Marco, Luis, Morillo, Valery, Gorriz, José Luis, Suarez, María K., Nava, Manuel, Ortega, Ángel, Parra, Heliana, Villasmil, Nelson, Rojas-Quintero, Joselyn, Bermúdez, Valmore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592766/
https://www.ncbi.nlm.nih.gov/pubmed/34790827
http://dx.doi.org/10.1155/2021/9032378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592766/
https://www.ncbi.nlm.nih.gov/pubmed/34790827
http://dx.doi.org/10.1155/2021/9032378

Ejemplares similares